Possibilities of new therapeutic strategies in brain tumors

Cancer Treatment Reviews

Volumn 36, Issue 4, 2010, Pages 335-341

  Bouffet, Eric ^a   Tabori, Uri ^a   Huang, Annie ^a   Bartels, Ute ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Chemotherapy; Molecularly targeted therapy; Pediatric brain tumors; Radiation; Surgery

Indexed keywords

CARBOPLATIN; CELECOXIB; CILENGITIDE; CLORETAZINE; CYCLOPHOSPHAMIDE; ETOPOSIDE; EVEROLIMUS; FLAVOPIRIDOL; GEFITINIB; IMATINIB; IRINOTECAN; LONAFARNIB; MAFOSFAMIDE; METHOTREXATE; SEMAXANIB; TEMOZOLOMIDE; THALIDOMIDE; TIPIFARNIB; TOPOTECAN; VINBLASTINE; VINCRISTINE;

BRAIN STEM TUMOR; BRAIN TUMOR; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CHILDHOOD CANCER; CLINICAL TRIAL; COMPUTER ASSISTED RADIOTHERAPY; CONTINUOUS INFUSION; CRANIOPHARYNGIOMA; DOSIMETRY; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG SAFETY; EPENDYMOMA; EVENT FREE SURVIVAL; FEASIBILITY STUDY; GASTROINTESTINAL TOXICITY; GERM CELL TUMOR; GLIOBLASTOMA; GLIOMA; GLIOSIS; HUMAN; INTENSITY MODULATED RADIATION THERAPY; MEDULLOBLASTOMA; MENINGITIS; NEUROECTODERM TUMOR; NEUROTOXICITY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; REVIEW; RHABDOID TUMOR; SURVIVAL RATE;

BRAIN NEOPLASMS; CHILD; COMBINED MODALITY THERAPY; HUMANS;

EID: 77953028361     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2010.02.009     Document Type: Review

References (78)

1. Magnani C., Aareleid T., Viscomi S., Pastore G., Berrino F. Variation in survival of children with central nervous system (CNS) malignancies diagnosed in Europe between 1978 and 1992: the EUROCARE study. Eur J Cancer 2001, 37(6):711-721.
2. Campbell J.W., Pollack I.F. Cerebellar astrocytomas in children. J Neurooncol 1996, 28(2-3):223-231.
3. Benesch M., Eder H.G., Sovinz P., Raith J., Lackner H., Moser A., et al. Residual or recurrent cerebellar low-grade glioma in children after tumor resection: is re-treatment needed? A single center experience from 1983 to 2003. Pediatr Neurosurg 2006, 42(3):159-164.
4. Qaddoumi I., Sultan I., Broniscer A. Pediatric low-grade gliomas and the need for new options for therapy: why and how?. Cancer Biol Ther 2009, 8. (1).
5. Muller H.L., Albanese A., Calaminus G., Hargrave D., Garre M.L., Gebhardt U., et al. Consensus and perspectives on treatment strategies in childhood craniopharyngioma: results of a meeting of the Craniopharyngioma Study Group (SIOP), Genova, 2004. J Pediatr Endocrinol Metab 2006, 19(Suppl. 1):453-454.
6. Fisher P.G., Jenab J., Gopldthwaite P.T., Tihan T., Wharam M.D., Foer D.R., et al. Outcomes and failure patterns in childhood craniopharyngiomas. Childs Nerv Syst 1998, 14(10):558-563.
7. Palma L., Celli P., Mariottini A. Long-term follow-up of childhood cerebellar astrocytomas after incomplete resection with particular reference to arrested growth or spontaneous tumour regression. Acta Neurochir (Wien) 2004, 146(6):581-588. [discussion 588].
8. Bouffet E., Baranzelli M.C., Patte C., Portas M., Edan C., Chastagner P., et al. Combined treatment modality for intracranial germinomas: results of a multicentre SFOP experience. Societe Francaise d'Oncologie Pediatrique. Br J Cancer 1999, 79(7-8):1199-1204.
9. Finlay J., da Silva N.S., Lavey R., Bouffet E., Kellie S.J., Shaw E., et al. The management of patients with primary central nervous system (CNS) germinoma: current controversies requiring resolution. Pediatr Blood Cancer 2008, 51(2):313-316.
10. Gajjar A., Chintagumpala M., Ashley D., Kellie S., Kun L.E., Merchant T.E., et al. Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial. Lancet Oncol 2006, 7(10):813-820.
11. Packer R.J., Gajjar A., Vezina G., Rorke-Adams L., Burger P.C., Robertson P.L., et al. Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma. J Clin Oncol 2006, 24(25):4202-4208.
12. Merchant T.E., Fouladi M. Ependymoma: new therapeutic approaches including radiation and chemotherapy. J Neurooncol 2005, 75(3):287-299.
13. Merchant T.E., Mulhern R.K., Krasin M.J., Kun L.E., Williams T., Li C., et al. Preliminary results from a phase II trial of conformal radiation therapy and evaluation of radiation-related CNS effects for pediatric patients with localized ependymoma. J Clin Oncol 2004, 22(15):3156-3162.
14. Broniscer A. Past, present, and future strategies in the treatment of high-grade glioma in children. Cancer Invest 2006, 24(1):77-81.
15. Hargrave D., Bartels U., Bouffet E. Diffuse brainstem glioma in children: critical review of clinical trials. Lancet Oncol 2006, 7(3):241-248.
16. MacDonald T.J. Aggressive infantile embryonal tumors. J Child Neurol 2008, 23(10):1195-1204.
17. Rutkowski S., Bode U., Deinlein F., Ottensmeier H., Warmuth-Metz M., Soerensen N., et al. Treatment of early childhood medulloblastoma by postoperative chemotherapy alone. N Engl J Med 2005, 352(10):978-986.
18. Dunkel I.J., Boyett J.M., Yates A., Rosenblum M., Garvin J.H., Bostrom B.C., et al. High-dose carboplatin, thiotepa, and etoposide with autologous stem-cell rescue for patients with recurrent medulloblastoma. Children's Cancer Group. J Clin Oncol 1998, 16(1):222-228.
19. Mason W.P., Goldman S., Yates A.J., Boyett J., Li H., Finlay J.L. Survival following intensive chemotherapy with bone marrow reconstitution for children with recurrent intracranial ependymoma - a report of the Children's Cancer Group. J Neurooncol 1998, 37(2):135-143.
20. Finlay J.L., Dhall G., Boyett J.M., Dunkel I.J., Gardner S.L., Goldman S., et al. Myeloablative chemotherapy with autologous bone marrow rescue in children and adolescents with recurrent malignant astrocytoma: outcome compared with conventional chemotherapy: a report from the Children's Oncology Group. Pediatr Blood Cancer 2008, 51(6):806-811.
21. Gururangan S., Dunkel I.J., Goldman S., Garvin J.H., Rosenblum M., Boyett J.M., et al. Myeloablative chemotherapy with autologous bone marrow rescue in young children with recurrent malignant brain tumors. J Clin Oncol 1998, 16(7):2486-2493.
22. Kalifa C., Hartmann O., Demeocq F., Vassal G., Couanet D., Terrier-Lacombe M.J., et al. High-dose busulfan and thiotepa with autologous bone marrow transplantation in childhood malignant brain tumors: a phase II study. Bone Marrow Transplant 1992, 9(4):227-233.
23. Massimino M., Gandola L., Spreafico F., Biassoni V., Luksch R., Collini P., et al. No salvage using high-dose chemotherapy plus/minus reirradiation for relapsing previously irradiated medulloblastoma. Int J Radiat Oncol Biol Phys 2008.
24. Gajjar A. High-dose chemotherapy for recurrent medulloblastoma: time for a reappraisal. Cancer 2008, 112(8):1643-1645.
25. Pollack I.F., Gerszten P.C., Martinez A.J., Lo K.H., Shultz B., Albright A.L., et al. Intracranial ependymomas of childhood: long-term outcome and prognostic factors. Neurosurgery 1995, 37(4):655-666. [discussion 666-7].
26. Zeltzer P.M., Boyett J.M., Finlay J.L., Albright A.L., Rorke L.B., Milstein J.M., et al. Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastoma in children: conclusions from the Children's Cancer Group 921 randomized phase III study. J Clin Oncol 1999, 17(3):832-845.
27. Berger C., Thiesse P., Lellouch-Tubiana A., Kalifa C., Pierre-Kahn A., Bouffet E. Choroid plexus carcinomas in childhood: clinical features and prognostic factors. Neurosurgery 1998, 42(3):470-475.
28. Hilden J.M., Meerbaum S., Burger P., Finlay J., Janss A., Scheithauer B.W., et al. Central nervous system atypical teratoid/rhabdoid tumor: results of therapy in children enrolled in a registry. J Clin Oncol 2004, 22(14):2877-2884.
29. Finlay J.L., Wisoff J.H. The impact of extent of resection in the management of malignant gliomas of childhood. Childs Nerv Syst 1999, 15(11-12):786-788.
30. Albright A.L., Wisoff J.H., Zeltzer P., Boyett J., Rorke L.B., Stanley P., et al. Prognostic factors in children with supratentorial (nonpineal) primitive neuroectodermal tumors. A neurosurgical perspective from the Children's Cancer Group. Pediatr Neurosurg 1995, 22(1):1-7.
31. Roujeau T., Machado G., Garnett M.R., Miquel C., Puget S., Geoerger B., et al. Stereotactic biopsy of diffuse pontine lesions in children. J Neurosurg 2007, 107(Suppl. 1):1-4.
32. Song D.K., Lonser R.R. Convection-enhanced delivery for the treatment of pediatric neurologic disorders. J Child Neurol 2008, 23(10):1231-1237.
33. Groothuis D.R., Benalcazar H., Allen C.V., Wise R.M., Dills C., Dobrescu C., et al. Comparison of cytosine arabinoside delivery to rat brain by intravenous, intrathecal, intraventricular and intraparenchymal routes of administration. Brain Res 2000, 856(1-2):281-290.
34. Bomgaars L.R., Bernstein M., Krailo M., Kadota R., Das S., Chen Z., et al. Phase II trial of irinotecan in children with refractory solid tumors: a Children's Oncology Group Study. J Clin Oncol 2007, 25(29):4622-4627.
35. Turner C.D., Gururangan S., Eastwood J., Bottom K., Watral M., Beason R., et al. Phase II study of irinotecan (CPT-11) in children with high-risk malignant brain tumors: the Duke experience. Neuro Oncol 2002, 4(2):102-108.
36. Nicholson H.S., Kretschmar C.S., Krailo M., Bernstein M., Kadota R., Fort D., et al. Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group. Cancer 2007, 110(7):1542-1550.
37. Stupp R., Mason W.P., van den Bent M.J., Weller M., Fisher B., Taphoorn M.J., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005, 352(10):987-996.
38. Cohen K., Heideman R., Zhou T., Holmes E., Burger P., Brat D., et al. Should temozolomide be the standard of care for children with newly diagnosed high -grade gliomas? Results of the Children's Oncology Group ACNS0126 Study. Neuro-oncology 2007, 9(2):188.
39. Smith M.E., Cimica V., Chinni S., Challagulla K., Mani S., Kalpana G.V. Rhabdoid tumor growth is inhibited by flavopiridol. Clin Cancer Res 2008, 14(2):523-532.
40. Moghrabi A, Hershon L, Rousseau P, Decarie JC, Friedman HS, Zhou T, et al. A phase I/II feasibility study of oral etoposide given concurrently with radiotherapy followed with dose-intensive adjuvant chemotherapy for children with newly diagnosed high-risk medulloblastoma COG P9631. In: 13th international symposium on pediatric neuro-oncology 2008 JUN 29-JUL 02, 2008; Chicago, IL: Neuro-oncology; 2008. p. 476.
41. Jakacki RI, Burger PC, Zhou T, Holmes E, Packer R, Goldwein J, et al. Outcome for metastatic (M+) medulloblastoma (MB) treated with carboplatin during craniospinal radiotherapy (CSRT) followed by cyclophosphamide (CPM) and vincristine (VCR): Preliminary results of COG 99701. In: 2007 ASCO annual meeting 2007; 2007. p. 2017.
42. ACNS0332. http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=511991&version=patient&protocolsearchid=5798903.
43. Stempak D, Gammon J, Stephens D, Feltis A, Bartels U, Fryer C, et al. A Canadian multicenter pilot study of extended low-dose temozolomide and radiation therapy in pediatric brainstem glioma. In: 13th international symposium on pediatric neuro-oncology; 2008; Chicago, IL: Neuro-oncology; 2008. p. 391.
44. Modak S., Gardner S., Dunkel I.J., Balmaceda C., Rosenblum M.K., Miller D.C., et al. Thiotepa-based high-dose chemotherapy with autologous stem-cell rescue in patients with recurrent or progressive CNS germ cell tumors. J Clin Oncol 2004, 22(10):1934-1943.
45. Bouffet E., Doz F., Demaille M.C., Tron P., Roche H., Plantaz D., et al. Improving survival in recurrent medulloblastoma: earlier detection, better treatment or still an impasse?. Br J Cancer 1998, 77(8):1321-1326.
46. Chi S.N., Gardner S.L., Levy A.S., Knopp E.A., Miller D.C., Wisoff J.H., et al. Feasibility and response to induction chemotherapy intensified with high-dose methotrexate for young children with newly diagnosed high-risk disseminated medulloblastoma. J Clin Oncol 2004, 22(24):4881-4887.
47. Foreman N.K., Schissel D., Le T., Strain J., Fleitz J., Quinones R., et al. A study of sequential high dose cyclophosphamide and high dose carboplatin with peripheral stem-cell rescue in resistant or recurrent pediatric brain tumors. J Neurooncol 2005, 71(2):181-187.
48. Hanahan D., Bergers G., Bergsland E. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest 2000, 105(8):1045-1047.
49. Broxterman H.J., Lankelma J., Hoekman K. Resistance to cytotoxic and anti-angiogenic anticancer agents: similarities and differences. Drug Resist Updat 2003, 6(3):111-127.
50. Baruchel S., Diezi M., Hargrave D., Stempak D., Gammon J., Moghrabi A., et al. Safety and pharmacokinetics of temozolomide using a dose-escalation, metronomic schedule in recurrent paediatric brain tumours. Eur J Cancer 2006, 42(14):2335-2342.
51. Stempak D., Gammon J., Halton J., Moghrabi A., Koren G., Baruchel S. A pilot pharmacokinetic and antiangiogenic biomarker study of celecoxib and low-dose metronomic vinblastine or cyclophosphamide in pediatric recurrent solid tumors. J Pediatr Hematol Oncol 2006, 28(11):720-728.
52. Ashley D.M., Meier L., Kerby T., Zalduondo F.M., Friedman H.S., Gajjar A., et al. Response of recurrent medulloblastoma to low-dose oral etoposide. J Clin Oncol 1996, 14(6):1922-1927.
53. Lafay-Cousin L., Holm S., Qaddoumi I., Nicolin G., Bartels U., Tabori U., et al. Weekly vinblastine in pediatric low-grade glioma patients with carboplatin allergic reaction. Cancer 2005, 103(12):2636-2642.
54. Kieran M.W., Turner C.D., Rubin J.B., Chi S.N., Zimmerman M.A., Chordas C., et al. A feasibility trial of antiangiogenic (metronomic) chemotherapy in pediatric patients with recurrent or progressive cancer. J Pediatr Hematol Oncol 2005, 27(11):573-581.
55. Slavc I., Schuller E., Falger J., Gunes M., Pillwein K., Czech T., et al. Feasibility of long-term intraventricular therapy with mafosfamide (n=26) and etoposide (n=11): experience in 26 children with disseminated malignant brain tumors. J Neurooncol 2003, 64(3):239-247.
56. Blaney S.M., Boyett J., Friedman H., Gajjar A., Geyer R., Horowtiz M., et al. Phase I clinical trial of mafosfamide in infants and children aged 3 years or younger with newly diagnosed embryonal tumors: a pediatric brain tumor consortium study (PBTC-001). J Clin Oncol 2005, 23(3):525-531.
57. Blaney S.M., Heideman R., Berg S., Adamson P., Gillespie A., Geyer J.R., et al. Phase I clinical trial of intrathecal topotecan in patients with neoplastic meningitis. J Clin Oncol 2003, 21(1):143-147.
58. Habrand J.L., De Crevoisier R. Radiation therapy in the management of childhood brain tumors. Childs Nerv Syst 2001, 17(3):121-133.
59. Penagaricano J.A., Papanikolaou N., Yan Y., Ratanatharathorn V. Application of intensity-modulated radiation therapy for pediatric malignancies. Med Dosim 2004, 29(4):247-253.
60. Yock T.I., Tarbell N.J. Technology insight: proton beam radiotherapy for treatment in pediatric brain tumors. Nat Clin Pract Oncol 2004, 1(2):97-103. [quiz 1 p following 111].
61. MacDonald S.M., Safai S., Trofimov A., Wolfgang J., Fullerton B., Yeap B.Y., et al. Proton radiotherapy for childhood ependymoma: initial clinical outcomes and dose comparisons. Int J Radiat Oncol Biol Phys 2008, 71(4):979-986.
62. Merchant T.E., Hua C.H., Shukla H., Ying X., Nill S., Oelfke U. Proton versus photon radiotherapy for common pediatric brain tumors: comparison of models of dose characteristics and their relationship to cognitive function. Pediatr Blood Cancer 2008, 51(1):110-117.
63. Zacharatou Jarlskog C., Paganetti H. Risk of developing second cancer from neutron dose in proton therapy as function of field characteristics, organ, and patient age. Int J Radiat Oncol Biol Phys 2008, 72(1):228-235.
64. Hodgson D.C., Goumnerova L.C., Loeffler J.S., Dutton S., Black P.M., Alexander E., et al. Radiosurgery in the management of pediatric brain tumors. Int J Radiat Oncol Biol Phys 2001, 50(4):929-935.
65. Merchant T.E., Boop F.A., Kun L.E., Sanford R.A. A retrospective study of surgery and reirradiation for recurrent ependymoma. Int J Radiat Oncol Biol Phys 2008, 71(1):87-97.
66. Pollack I.F., Jakacki R.I., Blaney S.M., Hancock M.L., Kieran M.W., Phillips P., et al. Phase I trial of imatinib in children with newly diagnosed brainstem and recurrent malignant gliomas: a Pediatric Brain Tumor Consortium report. Neuro Oncol 2007, 9(2):145-160.
67. Geyer JR, Boyett J, Douglas J, Phillips P, Young-Poussaint T, Packer R, et al. Phase I Trial of ZD1839 (IressaTM) and radiation in pediatric patients newly diagnosed with brain stem tumors or incompletely resected supratentorial malignant gliomas. In: ASTRO 46th annual meeting, 2004. Atlanta: International Journal of Radiation Oncology Biology Physics; 2004. p. S251.
68. Fouladi M., Laningham F., Wu J., O'Shaughnessy M.A., Molina K., Broniscer A., et al. Phase I study of everolimus in pediatric patients with refractory solid tumors. J Clin Oncol 2007, 25(30):4806-4812.
69. Kieran M.W., Packer R.J., Onar A., Blaney S.M., Phillips P., Pollack I.F., et al. Phase I and pharmacokinetic study of the oral farnesyltransferase inhibitor lonafarnib administered twice daily to pediatric patients with advanced central nervous system tumors using a modified continuous reassessment method: a Pediatric Brain Tumor Consortium Study. J Clin Oncol 2007, 25(21):3137-3143.
70. Kieran M.W., Supko J.G., Wallace D., Fruscio R., Poussaint T.Y., Phillips P., et al. Phase I study of SU5416, a small molecule inhibitor of the vascular endothelial growth factor receptor (VEGFR) in refractory pediatric central nervous system tumors. Pediatr Blood Cancer 2009, 52(2):169-176.
71. MacDonald T.J., Stewart C.F., Kocak M., Goldman S., Ellenbogen R.G., Phillips P., et al. Phase I clinical trial of cilengitide in children with refractory brain tumors: Pediatric Brain Tumor Consortium Study PBTC-012. J Clin Oncol 2008, 26(6):919-924.
72. Gururangan S., Turner C.D., Stewart C.F., O'Shaughnessy M., Kocak M., Poussaint T.Y., et al. Phase I trial of VNP40101M (Cloretazine) in children with recurrent brain tumors: a pediatric brain tumor consortium study. Clin Cancer Res 2008, 14(4):1124-1130.
73. Daw N.C., Furman W.L., Stewart C.F., Iacono L.C., Krailo M., Bernstein M.L., et al. Phase I and pharmacokinetic study of gefitinib in children with refractory solid tumors: a Children's Oncology Group Study. J Clin Oncol 2005, 23(25):6172-6180.
74. Fouladi M., Nicholson H.S., Zhou T., Laningham F., Helton K.J., Holmes E., et al. A phase II study of the farnesyl transferase inhibitor, tipifarnib, in children with recurrent or progressive high-grade glioma, medulloblastoma/primitive neuroectodermal tumor, or brainstem glioma: a Children's Oncology Group study. Cancer 2007, 110(11):2535-2541.
75. Haas-Kogan D.A., Banerjee A., Kocak M., Prados M.D., Geyer J.R., Fouladi M., et al. Phase I trial of tipifarnib in children with newly diagnosed intrinsic diffuse brainstem glioma. Neuro Oncol 2008, 10(3):341-347.
76. Franz D.N., Leonard J., Tudor C., Chuck G., Care M., Sethuraman G., et al. Rapamycin causes regression of astrocytomas in tuberous sclerosis complex. Ann Neurol 2006, 59(3):490-498.
77. Kun L.E., Gajjar A., Muhlbauer M., Heideman R.L., Sanford R., Brenner M., et al. Stereotactic injection of herpes simplex thymidine kinase vector producer cells (PA317-G1Tk1SvNa. 7) and intravenous ganciclovir for the treatment of progressive or recurrent primary supratentorial pediatric malignant brain tumors. Hum Gene Ther 1995, 6(9):1231-1255.
78. Packer R.J., Raffel C., Villablanca J.G., Tonn J.C., Burdach S.E., Burger K., et al. Treatment of progressive or recurrent pediatric malignant supratentorial brain tumors with herpes simplex virus thymidine kinase gene vector-producer cells followed by intravenous ganciclovir administration. J Neurosurg 2000, 92(2):249-254.